Karyopharm Announces Three Clinical Data Presentations at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Karyopharm Announces Three Clinical Data Presentations at ESMO 2014

NEWTON, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a clinical-stage pharmaceutical company, today announced that clinical and preclinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be presented at the 2014 Congress of the European Society for Medical Oncology (ESMO), which is being held from September 26-30, 2014 in Madrid, Spain. Clinical results to be presented include updated data from Karyopharm's Phase 1 studies in patients with advanced solid tumors.

Oral Presentation:

Monday, September 29, 2014, 2:00 – 3:45 p.m. CEST
Title : Selinexor (KPT-330), an Oral, Selective Inhibitor of Nuclear Export (SINE) Shows Anti-Prostate Cancer (PrCa) Activity Preclinically & Disease Control in Patients (pts) with Chemotherapy Refractory, Castrate-Resistant Prostate Cancer (CRPC). (Presentation #758O)
Presenter : Hemchandra Mahaseth, MD
Location : Madrid Conference Area

Poster Presentations:

Sunday, September 28, 2014, 1:00 – 2:00 p.m. CEST (poster highlights presentation)
Title : Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Head & Neck Squamous Cell Carcinoma (HN-SCC). (Discussion #994PD)
Presenter : Amit Mahipal, MD
Location : Bilbao Conference Area

Saturday, September 27, 2014, 12:45 – 1:45 p.m. CEST (poster presentation)
Title : Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients (pts) with Platinum Resistant/Refractory Ovarian Cancer (OvCa). (Poster #888P)
Presenter : John Martignetti, MD, PhD
Location : Poster Area

About Selinexor

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. Over 400 patients have been treated with Selinexor in Phase 1 and Phase 2 clinical trials in advanced hematologic malignancies and solid tumors. Additional Phase 1 and Phase 2 studies are ongoing or currently planned and three registration-directed clinical trials in hematological indications are expected to begin enrollment during 2014. The latest clinical trial information for Selinexor is available at www.clinicaltrials.gov .

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing.  Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information about Karyopharm, please visit www.karyopharm.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE compounds, including Selinexor (KPT-330), or any other drug candidate that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission (SEC), and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Justin Renz (617) 658-0574

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 6

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 138

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 41

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 179

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 61

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 153

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 114

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 192

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 56

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 200

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Market Dynamics: Dollar Strength and Economic Trends

Updated Category News Views 280

Understanding Current Market Trends In today's financial landscape, the dollar has been showing significant strength, propelled largely by the increasing yields of U.S. Treasuries. This upswing marks the dollar reaching levels not seen in nearly three months against both the euro and the yen, signaling contrasting economic conditions across these regions. Economic...

Continue Reading
Bitcoin Surpasses $99K: Insights on Market Movements

Updated Category News Views 245

Bitcoin's Impressive Recovery Journey Bitcoin has displayed remarkable resilience in the market, experiencing gains for the seventh consecutive day with its price hitting $99,513.7. This uptrend comes after a challenging year-end period that saw a significant dip in value. As investors closely monitor the evolving regulatory outlook in the United States under the...

Continue Reading
StoneX Group Inc. Prepares for First Quarter Earnings Release

Updated Category News Views 102

StoneX Group Inc. Prepares for Earnings Release StoneX Group Inc. (NASDAQ: SNEX) is gearing up to share its fiscal 2025 first quarter financial results. This release is scheduled for a date soon to come, creating excitement within the investment community. As a part of its commitment to transparency and investor engagement, the company will host a conference call the...

Continue Reading
Down4Sound Introduces High-Power DVX Subwoofer Series

Updated Category News Views 82

Down4Sound Launches Exciting New DVX Subwoofer Series Down4Sound, a renowned name in high-performance car audio systems, has announced the introduction of their groundbreaking DVX Subwoofer Series. This innovative product line promises to redefine audio experiences for enthusiasts everywhere, boasting a phenomenal 1700W RMS power output across multiple size options to...

Continue Reading
Jozu Boosts AI Deployment Speed and Strengthens Security Efforts

Updated Category News Views 365

Accelerating AI Deployment with Jozu Jozu has unveiled an innovative enterprise AI orchestration platform that significantly reduces the time required for deploying AI applications while enhancing security and compliance protocols. This platform addresses the increasing demands faced by organizations in managing AI applications effectively. Enhancing AI Management Across...

Continue Reading